RxDoctor Payments Data

Jennifer Carlile

Family · Marana, AZNPI 1609217256

Payments from drug & device makers

$1,610in general payments, 2019–2025

Across 62 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$251
  • AbbVie$237
  • Biohaven Pharmaceuticals, Inc.$160
  • AstraZeneca$151
  • Stryker$122
  • Kestra Medical Technology Services, Inc.$121
  • plus $568 from 17 others

What the payments were for

  • Food & beverage$1,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,610 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$3,434
Medicare patients
59
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$166,123
TrulicityDulaglutide131$151,702
EliquisApixaban60$76,645
JardianceEmpagliflozin44$65,715
FarxigaDapagliflozin Propanediol27$45,122
MounjaroTirzepatide33$42,676
ProliaDenosumab18$29,977
XareltoRivaroxaban16$28,389
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$22,275
JanuviaSitagliptin Phosphate11$20,111
Stiolto RespimatTiotropium Br/Olodaterol Hcl40$18,644
InvokanaCanagliflozin17$15,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,671
Breo ElliptaFluticasone/Vilanterol31$13,937
MyrbetriqMirabegron17$11,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$44$194,378164 claims
Novo NordiskOzempic$37$166,123150 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Synjardy Xr$13$98,900107 claims
PfizerEliquis$30$76,64560 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Shingrix$28$59,135104 claims
AstraZenecaFarxiga, Symbicort$151$51,60955 claims
AmgenProlia$48$29,97718 claims
MerckJanuvia$24$20,11111 claims
AbbVieSynthroid$237$1,83622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Marana

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →